Hikma Pharmaceutical | HIK - Operating Expenses


Hikma Pharmaceutical reported $1.34B in Operating Expenses for its fiscal semester ending in December of 2025.





Operating Expenses Change Date
Almirall EUR 517.4M 32K Dec/2025
argenx SE USD 904M 10.57M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Autolus Therapeutics Ltd USD 85.73M 11.02M Mar/2026
Bayer EUR 9.88B 452M Mar/2026
Fresenius EUR 5.25B 337M Dec/2025
Genmab DKK 798M 235M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
GRIFOLS EUR 1.45B 255.28M Mar/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Lakefront Biotherapeutics EUR 70.18M 50.08M Mar/2026
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.09B 687M Mar/2026
Orion EUR 302.9M 64.2M Mar/2026
Recordati EUR 482.31M 98.3M Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
UCB EUR 2.96B 196M Dec/2025